Effect fingerprinting of new psychoactive substances (NPS): What can we learn from in vitro data?
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
The use of new psychoactive substances (NPS) is increasing and currently > 600 NPS have been reported. However, limited information on neuropharmacological and toxicological effects of NPS is available, hampering risk characterization. We reviewed the literature on the in vitro neuronal modes of action to obtain effect fingerprints of different classes of illicit drugs and NPS. The most frequently reported NPS were selected for review: cathinones (MDPV, α-PVP, mephedrone, 4-MEC, pentedrone, methylone), cannabinoids (JWH-018), (hallucinogenic) phenethylamines (4-fluoroamphetamine, benzofurans (5-APB, 6-APB), 2C-B, NBOMes (25B-NBOMe, 25C-NBOMe, 25I-NBOMe)), arylcyclohexylamines (methoxetamine) and piperazine derivatives (mCPP, TFMPP, BZP). Our effect fingerprints highlight the main modes of action for the different NPS studied, including inhibition and/or reversal of monoamine reuptake transporters (cathinones and non-hallucinogenic phenethylamines), activation of 5-HT2receptors (hallucinogenic phenethylamines and piperazines), activation of cannabinoid receptors (cannabinoids) and inhibition of NDMA receptors (arylcyclohexylamines). Importantly, we identified additional targets by relating reported effect concentrations to the estimated human brain concentrations during recreational use. These additional targets include dopamine receptors, α- and β-adrenergic receptors, GABAAreceptors and acetylcholine receptors, which may all contribute to the observed clinical symptoms following exposure. Additional data is needed as the number of NPS continues to increase. Also, the effect fingerprints we have obtained are still incomplete and suffer from a large variation in the reported effects and effect sizes. Dedicated in vitro screening batteries will aid in complementing specific effect fingerprints of NPS. These fingerprints can be implemented in the risk assessments of NPS that are necessary for eventual control measures to reduce Public Health risks.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Koob, G. F., & Volkow, N. D. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.110 · Cited by 5,340
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609
The Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”)
Green, A. R., Mechan, A. O., Elliott, J. M., O’Shea, E., & Colado, M. I. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.3.3 · Cited by 1,272
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
The endocannabinoid system and its therapeutic exploitation
Marzo, V. D., Bifulco, M., & Petrocellis, L. D. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1495 · Cited by 1,090 · cited 2×
“CB1 receptors are amongst the most abundant GPCRs in the central nervous system, although they are also present in the peripheral nervous system (Di Marzo, Bifulco, & Petrocellis, 2004).”
Imaging dopamine's role in drug abuse and addiction
Volkow, N. D., Fowler, J. S., Wang, G. J., Baler, R., & Telang, F. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.05.022 · Cited by 988
New Insights into the Mechanism of Action of Amphetamines
Fleckenstein, A. E., Volz, T. J., Riddle, E. L., Gibb, J. W., & Hanson, G. R. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105140 · Cited by 731 · cited 1×
“1) (Fleckenstein, Volz, Riddle, Gibb, & Hanson, 2007; Gowrishankar, Hahn, & Blakely, 2014; Korpi et al., 2015; Rietjens, Hondebrink, Westerink, & Meulenbelt, 2012; Torres, Gainetdinov, & Caron, 2003; Verrico, Miller, & Madras, 2007; Williams & Galli, 2006).”
Rothman, R. B., Baumann, M. H., Savage, J. E., Rauser, L., McBride, A., Hufeisen, S. J., & Roth, B. L. (2000) · Circulation · doi:10.1161/01.cir.102.23.2836 · Cited by 722 · cited 1×
“Piperazines: (Nagai et al., 2007; Simmler, Rickli, Schramm, et al., 2014; Baumann et al., 2014; Baumann et al., 2004; Rothman & Baumann, 2002; Samanin et al., 1979; Baumann et al., 2000; Rothman et al., 2010; Gobbi et al., 2002).”
Kapur, S., & Seeman, P. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001093 · Cited by 459
The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain
Nagai, F., Nonaka, R., & Satoh Hisashi Kamimura, K. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.11.075 · Cited by 279
Ketamine abuse potential and use disorder
Liu, Y., Lin, D., Wu, B., & Zhou, W. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.05.016 · Cited by 256
Moghaddam, B., & Krystal, J. H. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs075 · Cited by 238 · cited 1×
“Just like PCP (Grayson et al., 2016; Mouri, Noda, Enomoto, & Nabeshima, 2007), ketamine has therefore been used for decades to produce rodent models of schizophrenia (Javitt, 2004; Moghaddam & Krystal, 2012).”
A REVIEW OF KETAMINE ABUSE AND DIVERSION: Review: Ketamine
Sassano-Higgins, S., Baron, D., Juarez, G., Esmaili, N., & Gold, M. (2016) · Depression and Anxiety · doi:10.1002/da.22536 · Cited by 204
Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics
Seeman, P., Ko, F., & Tallerico, T. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001682 · Cited by 200
Moaddel, R., Abdrakhmanova, G., Kozak, J., Jozwiak, K., Toll, L., Jimenez, L., Rosenberg, A., Tran, T., Xiao, Y., Zarate, C. A., et al. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.11.023 · Cited by 176
Antidepressant actions of ketamine: from molecular mechanisms to clinical practice
Monteggia, L. M., & Zarate, C. (2015) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2014.12.004 · Cited by 149 · cited 1×
“On the other hand, ketamine primarily inhibits the glutamate N-methyl-D-aspartate (NMDA) receptor (Monteggia & Zarate, 2015), inducing hallucinations and the feeling of dissociation.”
Mechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse
Korpi, E. R., den Hollander, B., Farooq, U., Vashchinkina, E., Rajkumar, R., Nutt, D. J., Hyytiä, P., & Dawe, G. S. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010967 · Cited by 148 · cited 1×
“1) (Fleckenstein, Volz, Riddle, Gibb, & Hanson, 2007; Gowrishankar, Hahn, & Blakely, 2014; Korpi et al., 2015; Rietjens, Hondebrink, Westerink, & Meulenbelt, 2012; Torres, Gainetdinov, & Caron, 2003; Verrico, Miller, & Madras, 2007; Williams & Galli, 2006).”
From “Special K” to “Special M”: The Evolution of the Recreational Use of Ketamine and Methoxetamine
Corazza, O., Assi, S., & Schifano, F. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12063 · Cited by 146 · cited 5×
“…induces more severe psychotropic e ff ects (known as the “ K-hole ” ) that can range from vivid dreams and hallucinations, to fl ashbacks, confusion, dissociation, depersonalization and in more severe cases to psychosis and near-death experiences (Corazza et al., 2013; Morgan & Curran, 2011).”
InfluentialKetamine inhibits monoamine transporters expressed in human embryonic kidney 293 cells
Nishimura, M., Sato, K., Okada, T., Yoshiya, I., Schloss, P., Shimada, S., & Tohyama, M. (1998) · Anesthesiology · doi:10.1097/00000542-199803000-00029 · Cited by 128
Can, A., Zanos, P., Moaddel, R., Kang, H. J., Dossou, K. S. S., Wainer, I. W., Cheer, J. F., Frost, D. O., Huang, X.-P., & Gould, T. D. (2016) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.235838 · Cited by 115
Novel halogenated derivates of JWH-018: behavioral and binding studies in mice
Vigolo, A., Ossato, A., Trapella, C., Vincenzi, F., Rimondo, C., Seri, C., Varani, K., Serpelloni, G., & Marti, M. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.02.008 · Cited by 91
Synthesis and N-Methyl-d-aspartate (NMDA) Receptor Activity of Ketamine Metabolites
Morris, P. J., Moaddel, R., Zanos, P., Moore, C. E., Gould, T., Zarate, C. A., & Thomas, C. J. (2017) · Organic Letters · doi:10.1021/acs.orglett.7b02177 · Cited by 83
Glennon, R. A., Dukat, M., El-Bermawy, M., Law, H., De Los Angeles, J., Teitler, M., King, A., & Herrick-Davis, K. (1994) · Journal of Medicinal Chemistry · doi:10.1021/jm00039a004 · Cited by 67
Cited by
New psychoactive substances: a review and updates
Shafi, A., Berry, A. J., Sumnall, H., Wood, D. M., & Tracy, D. K. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320967197 · Cited by 347
Serotonin toxicity of serotonergic psychedelics
Malcolm, B., & Thomas, K. (2022) · Psychopharmacology · doi:10.1007/s00213-021-05876-x · Cited by 138
Applications and potential of in silico approaches for psychedelic chemistry
Karabulut, S., Kaur, H., & Gauld, J. W. (2023) · Molecules · doi:10.3390/molecules28165966 · Cited by 8
“Indeed, the diversity of reported in vitro data, the occurrence of multiple drug targets (combination of multiple receptor signals) for a single behavioral outcome, the limited availability of suitable experi ental techniques, and ethical considerations regarding human studies further complicate the acquisition of rel…”
Background
Metadata
- Authors
- Hondebrink, L., Zwartsen, A., & Westerink, R. H. S.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2018-02
- Volume
- 182
- Pages
- 193-224
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2766424089
- Cited by
- 80
- References
- 23
- FWCI
- 20.65
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.